

5-2-2015

Transplantation of Kidneys from Donors with Acute Renal Failure Five-Year Results from Double Center Experience

Ahmad Safra, MD

Thomas Jefferson University, ahmad.safra@jefferson.edu

Ashesh P. Shah, MD

Thomas Jefferson University, ashesh.shah@jefferson.edu

Cataldo Doria, MD, PhD

Jefferson Medical College - Thomas Jefferson University Hospital, cataldo.doria@jefferson.edu

Warren R Maley, MD

Thomas Jefferson University, Warren.Maley@jefferson.edu

Adam M. Frank, MD

*Thomas Jefferson University, adam.frank@jefferson.edu**See next page for additional authors*

[Let us know how access to this document benefits you](#)

Follow this and additional works at: <https://jdc.jefferson.edu/surgeryfp>Part of the [Surgery Commons](#)

Recommended Citation

Safra, MD, Ahmad; Shah, MD, Ashesh P.; Doria, MD, PhD, Cataldo; Maley, MD, Warren R; Frank, MD, Adam M.; Gorn, Chad; Lerner, RN, Laurel; Manley, Marie; and Ramirez, MD, Carlo B, "Transplantation of Kidneys from Donors with Acute Renal Failure Five-Year Results from Double Center Experience" (2015). *Department of Surgery Faculty Papers*. Paper 121. <https://jdc.jefferson.edu/surgeryfp/121>

Authors

Ahmad Safra, MD; Ashesh P. Shah, MD; Cataldo Doria, MD, PhD; Warren R Maley, MD; Adam M. Frank, MD; Chad Gorn; Laurel Lerner, RN; Marie Manley; and Carlo B Ramirez, MD



Transplantation of Kidneys from Donors with Acute Renal Failure

Five-Year Results from Double Center Experience

Ahmad Safra, MD¹, Ashesh Shah, MD^{1,2}, Cataldo Doria, MD, PhD^{1,2}, Warren Maley, MD^{1,2}, Adam Frank, MD^{1,2}, Chad Gorn¹, Laurel Lerner, RN², Marie Manley², Carlo Ramirez, MD^{1,2}



¹Division of Transplantation, Department of Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA;

²Kidney Transplant Program, Lankenau Medical Center, Wynnewood, PA, USA

Abstract

Background: Transplantation of kidneys from deceased donors with acute renal failure (ARF) has been described and represents an underutilized source of renal grafts. We reviewed retrospectively our double center experience with transplantation of ARF donor kidneys.

Methods: Between January 2009 and June 2014, we performed a total of 397 kidney transplants at the two hospitals. Of which, 65 came from donors with ARF. The outcome was compared with 62 expanded criteria donor kidneys and 270 standard criteria donor kidneys. ARF was defined as donor terminal creatinine higher than 2. All kidneys from ARF donors had acceptable biopsies and were pumped. The immunosuppression was similar in all three groups (Thymoglobulin for induction and Prograf, Cellcept and steroids for maintenance). The outcome measurements included recipient serum creatinine, patient and graft survival at 6 months, 1 year and 3 years. We also reviewed the delayed graft function (DGF) rates and cold ischemic time in all groups.

Results: Mean donor creatinine was 3.84±1.3. The 6 month, 1 and 3 year patient survival rates were 98.5%, 96.8% and 92.0% in ARF group, 98.1%, 97.0% and 93.4% SCD group and 98.4%, 93.2% and 77.7% in ECD group. The 6 month, 1 and 3 year death censored graft survival was 96.9%, 96.9%, 96.9% in ARF group, 97.7, 96.5, 91.8 in SCD group and 95.1%, 93.2%, 90.1% in ECD group. The mean 6mo, 1 year and 3 year recipient creatinine was 1.49, 1.46 and 1.51 in ARF group, 1.61, 1.72 and 1.77 in SCD group and 1.91, 1.92 and 2.15 in ECD group, respectively. ARF kidneys are noted to be associated with more DGF (58.5% in ARF group VS 41.5% in non ARF group), longer cold ischemic time (857.79 min in ARF group vs 589.32 min in non ARF group) and younger donor age (32.25 years in ARF group vs 40.65 years in non ARF group).

Conclusion: Elevated terminal donor creatinine is not a risk factor for graft loss after deceased donor kidney transplantation. Although there is increased risk of DGF and longer cold ischemic time, transplantation of ARF kidneys provides comparable short and long term graft function and patient survival compared to kidneys from non ARF donors.

Background

- Transplantation of kidneys from deceased donors with acute renal failure (ARF) has been described and represents an underutilized source of renal grafts
- We retrospectively reviewed our double center experience with transplantation of ARF donor kidneys

Methods

- 397 kidney transplants were performed from January 2009- June 2014 at TJUH and LMC
- 65 kidney grafts came from donors with ARF
- Outcome was compared with 62 expanded criteria donor (ECD) kidneys and 270 standard criteria donor (SCD) kidneys
- ARF was defined as donor terminal Creatinine > 2 mg/dl
- All kidney grafts from ARF donors had acceptable biopsies and were placed on machine perfusion pump
- Immunosuppression was similar in all three groups:
 - Induction: Thymoglobulin, steroid
 - Maintenance: Tacrolimus, MMF, steroids
- Outcome measurements included:
 - Recipient serum Creatinine
 - Delayed graft function (DGF) rates
 - Patient and graft survival rates at 6 months, 1 year and 3 years
- Cold ischemic times (CIT)

Results: Donor and Recipient Characteristics

	ARF	Non ARF	P-value
Donor Age (years)	32.3	40.7	<0.005
Terminal Donor Cr (mean)	4.20	0.97	<0.005
CIT (min)	857.8	589.3	<0.005
DGF (%)	58.5	41.5	<0.005

Results: Recipient Outcomes

Patient Survival (%)	ARF	SCD	ECD
6 months	98.5	98.1	98.4
1 year	96.8	97.0	93.2
3 years	92.0	93.4	77.7
Graft Survival (%)			
6 months	96.9	97.7	95.1
1 year	96.9	96.5	93.2
3 years	96.9	91.8	90.1
Recipient Creatinine (Mg/dl)			
6 months	1.49	1.61	1.91
1 year	1.46	1.72	1.92
3 years	1.51	1.77	2.15

Conclusions

- Elevated terminal donor Creatinine is not a risk factor for graft loss after deceased donor kidney transplantation
- Although there is increased risk of DGF and longer CIT, transplantation of ARF kidneys provides comparable short and long term graft function and patient survival compared to kidneys from non-ARF donors

The authors and co-authors have no financial disclosures